Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
139.4 USD | +0.24% | +0.60% | +5.83% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The firm trades with high earnings multiples: 29.61 times its 2024 earnings per share.
- With an enterprise value anticipated at 5.23 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.83% | 13.84B | C+ | ||
+1.10% | 105B | B+ | ||
+9.29% | 104B | B+ | ||
-3.00% | 22.09B | B | ||
-11.89% | 21.98B | B+ | ||
-26.59% | 20.17B | A- | ||
-5.20% | 19.49B | A- | ||
-6.58% | 17.75B | B | ||
+7.46% | 11.64B | D | ||
+28.56% | 11.55B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Neurocrine Biosciences, Inc. - Nasdaq
- Ratings Neurocrine Biosciences, Inc.